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Patient blood managementMore than 30% of the world's population are anemic with serious economic consequences including reduced
work capacity and other obstacles to national welfare and development. Red blood cell transfusion is the main-
stay to correct anemia, but it is also 1 of the top 5 overused procedures. Patient blood management (PBM) is a
proactive, patient-centered, and multidisciplinary approach to manage anemia, optimize hemostasis, minimize
iatrogenic blood loss, and harness tolerance to anemia. Although the World Health Organization has endorsed
PBM in 2010, many hospitals still seek guidance with the implementation of PBM in clinical routine. Given the
use of proven change management principles, we propose simple, cost-effective measures enabling any hospital
to reduce both anemia and red blood cell transfusions in surgical and medical patients. This article provides
comprehensive bundles of PBM components encompassing 107 different PBM measures, divided into 6 bundle
blocks acting as a working template to develop institutions' individual PBM practices for hospitals beginning a
program or trying to improve an already existing program. A stepwise selection of the most feasible measures
will facilitate the implementation of PBM. In this manner, PBM represents a new quality and safety standard.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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increasingly recognized as a risk factor for a number of adverse out-
comes, including hospitalization, morbidity, and mortality. The high
global prevalence of insufﬁciently treated anemia also possesses a
major economic burden including reduced work productivity and
increased social expenditures [1]. In hospitalized patients, incidence of
anemia increases within the processes of care, such as procedural
blood loss and phlebotomy [2].
Patient blood management (PBM), as deﬁned by the Society for
the Advancement of Blood Management [3], refers to “the timely appli-
cation of evidence based medical and surgical concepts designed to
maintain haemoglobin concentration, optimise haemostasis and mini-
mise blood loss in an effort to improve patient outcome.” It requires
rejecting the standard dogma and one-size-ﬁts-all approach, whereby
red blood cell (RBC) transfusions are used as the primary solution to
correct low hemoglobin levels in the hospitalized patient.
In recent years, a few reviews, standards, and guidelines have been
published providing detailed information on PBM [3–11]. Brieﬂy, PBM
must be executed by an institutionally empowered multidisciplinary
team that works in a concerted fashion with 4 guiding principles of
PBM: The ﬁrst principle or strategy is to manage the patient's anemia,
which primarily involves instituting methods of early detection and
using nutritional and pharmaceutical treatments to support erythropoie-
sis, if it is not mainly genetic or cancer related. While actively treating
anemia, the physiologic tolerance of anemia can be enhanced by mini-
mizing oxygen consumption and/or enhancing delivery. The second
PBM strategy involves optimizing coagulopathy. This involves determin-
ing the patient's current coagulation status and assessing those medica-
tions that affect this, correcting any abnormalities and, if present,
rapidly assessing the cause of bleeding. The third guiding PBM principle
entails using interdisciplinary blood conservation modalities. Physicians
can adhere to this principle by ensuring that their surgical techniques
are precise enough to minimize blood loss. Any blood loss should be
diagnosed and stopped immediately. In addition, intraoperative and
postoperative blood conservation techniques should be used, including
autologous conservation modalities. Attention should be given to phle-
botomy volume and frequency with the intent to minimize or eliminate
this common source of iatrogenic blood loss, which can either induce or
exacerbate anemia. The ﬁnal principle that also especially embodies the
overall PBM approach, and optimal blood use is the concept of patient-
centered decision making. This involves thorough communication with
the patient regarding his/her treatment. It is necessary to effectively
communicate the risks and beneﬁts of the various potential interventions
and to decide on the right course of action together with the patient.Please cite this article as: Meybohm P, et al, Patient Blood Management B
dx.doi.org/10.1016/j.tmrv.2016.05.012The patient's own preferences and values should be considered when
developing a medical plan [3,4,12].
There is a large amount of research evidence that the successful im-
plementation of PBM reduces perioperative blood loss and transfusion
needs [13–20], perioperative morbidity [13,16], mortality [14,16],
length of hospital stay [14,16], and costs [21]. In this respect, the
World Health Organization has ofﬁcially been urging member states to
implement PBM since 2010 (WHA63.12). Patient blood management
programs have already been rolled out successfully in some hospitals
in Western Australia [19], Europe [13,18], United States [14,17], and
now starting in Asia. Notable, outside Australia, no national PBM pro-
grams have been established, and many hospitals worldwide seek
guidance with its implementation.
Despite the demonstrated beneﬁts of PBM, many barriers and
challenges limit translation of PBM guidelines into clinical practice
[22–25], in particular due to lack of knowledge (eg, staff members are
not aware of the latest discoveries and new guidelines; imprudent prac-
tice is endorsed by common misconceptions), lack of interdisciplinary
commitment (eg, many patients have contact with different clinicians
from different departments with different opinions about the “best
treatment”; resistance from hospital's “culture”), lack of resources
(eg, limited staff with limited time; hospital administrators need to
invest initially before saving money), and concerns (eg, PBM may ini-
tially “cut down” jobs in blood donor service or transfusion medicine).
Strategies for overcoming the hurdles associated with incorporating
guidelines into clinical practice often include the use of multimodal
“care bundles.”
This article provides comprehensive bundles of PBM components
encompassingmore than100different PBMmeasures acting as aworking
template to develop institutions' individual PBM practices.
Methods
After an informalmeeting on PBM, held at Frankfurt in January 2015,
and attended by several of the authors (PM, CFW, SC, DS, and KZ), fur-
ther authors (TR, JI, AS, LTG, and MM) and a group developing an
European Guide on Good Practices for Patient Blood Management (AH
and HG) were invited to participate drafting a manuscript on a new
implementation concept, based on current practice and experience in
implementation of PBM of the authors, actively working in Australia,
Europe, and United States. During several revisions, comments and
contributions from the different authors to subsequent versions of
the manuscript were harmonized, until agreement on paper content
was reached. We would like to stress that this article contains theundles to Facilitate Implementation, Transfus Med Rev (2016), http://
3P. Meybohm et al. / Transfusion Medicine Reviews xxx (2016) xxx–xxxauthors' independent opinions based on experience as well as
evidence-based practices supported by clinical studies. No pharma-
ceutical company has funded the development or writing of the
manuscript. It is the primary aim of the authors to provide a new
tool/concept for change management process and to tackle the key
question “How to implement PBM.”
In this article, therefore, we propose simple, cost-effective measures
enabling any hospital to reduce both anemia and RBC transfusions
focusing on both the methodology of how and of what to implement.
The article refers to hospitals beginning a program or trying to improve
an already existing program. It is strongly recommended to enlarge
the scope of PBM to all subgroups of patients—surgical, medical, and
pediatric patients. Medical patients, for example, may present many
conditions that can be prevented or improved by PBM programs, for
example, renal anemia, blood loss due to chronic dialysis, massive
hemorrhage after gastrointestinal bleeding, hospital-acquired anemia
in intensive care patients, transfusion decision in hematology-
oncology patients, and others.
Results and Discussion
The “bundle” concept, asﬁrstly deﬁned by the Institute for Healthcare
Improvement (Cambridge, MA) in 2001, refers to “a straightforward
set of evidence-based interventions for a deﬁned patient population
that, when implemented together, will result in signiﬁcantly better,
more penetrating and sustainable outcomes than when implemented
individually” [26]. In other ﬁelds of complex interdisciplinary medicine,
for example, intensive care medicine, similar barriers could be ob-
served. To overcome these barriers, care bundles have been widely
implemented with success in terms of compliance to guidelines and
beneﬁcial impact on care processes and outcomes [27–31]. Thus, a
bundle for PBM is highly desired.
Similar to the bundle approach, a few nationwide health care quality
change initiatives were launched recently to overcome the barriers. For
example, the National Blood Authority of Australia has published a
“National Patient Blood Management Guidelines Implementation
Strategy” recommending the use of a multifaceted approach with
several tools to support the implementation of PBM and the appro-
priate transfusion practices [9]. In the UK, PBM has recently become
a quality improvement process initiated by the transfusion service
NHS Blood and Transplant [10]. The Consumers, Health and Food
Agency of the European Commission has initiated the developing of
a European Guide on Good Practices for Patient Blood Management,
focusing on the methodology of how and not primarily of what to
implement in terms of clinicalmodalities. This also includes the applica-
tion of proven change management methodologies for overcoming the
often deeply embedded cultural and institutional hurdles of behavior-
based medicine [32]. However, it is also important to have a more
clinical/technical template of what can be implemented and to identify
low hanging fruit in doing this, which is at the core of this approach of
PBM bundles [32,33].
Creating a PBM Program That Fits to the Local Hospital
An ideal PBM program would include a wide spectrum of adminis-
trative and clinical standards of PBM measures [3–12,34–42]. The
more components incorporated into clinical routine, the higher the
overall potential of a successful PBM program [9]. However, it is impor-
tant to respect that many important factors such as infrastructure, staff,
equipment, and economic resources greatly differ between hospitals
worldwide, and individualization is vitally important for the acceptance
of any new standard [43]. For this reason, PBM programs need to be
speciﬁcally designed according to local conditions.
Althoughrecent reviews [5,12,34–36] andguidelines/recommendations/
standards [3,6–8,10,11,37–42] provided detailed information on
what should be implemented and only a few reported strategies onPlease cite this article as: Meybohm P, et al, Patient Blood Management B
dx.doi.org/10.1016/j.tmrv.2016.05.012how PBM should be implemented [9], we now strongly suggest
that the implementation should be based on stepwise selection of
the most doable measures that ﬁt to the local hospital. To facilitate
the implementation of PBM in clinical routine, this article provides
a comprehensive checklist of multiple PBM bundles that can easily be
adoptedusing a stepwise approach by every institution. The PBMbundles
encompass 107 different PBM measures, divided into 6 bundle blocks.
The PBM bundles are based not only on the aforementioned guidelines/
recommendations [3,6–8,10,11,37–42], reviews [5,12,34–36], and the
Australian “National Patient BloodManagement Guidelines Implementa-
tion Strategy” [9] but also on the authors' experiences gleaned from
recent PBM activities in Australia [34,44], Europe [18,22,41,45–48], and
United States [14–16,49] and launching the German PBM Network [50].
Having success in PBM does not follow an “all-or-non-law,” but rather a
different grading of successful PBM implementation based on the total
number of measures achieved. The total number of points may then be
assigned to a semiquantitative PBM program level. Starting and having
small success thenmoving forwardwith larger steps is a recipe for higher
success. What small steps the hospital ﬁrst takes is certainly dependent
on that hospital, their resources, their faculty, and their administration.
This one of the most important strengths of our PBM bundle approach.
Where applicable, it may also provide a technical template/checklist
for both hospital audit and accreditation of PBM in future.
Patient Blood Management Bundles
A comprehensive PBMprogrammay includemore than 100 different
measures/tasks, divided into 4 bundle blocks according to the aforemen-
tioned four PBM strategies completed by 2 additional blocks providing
important information about general PBM project management and
PBM-related metrics. The more individual measures successfully imple-
mented in clinical routine, the higher the overall potential of PBM.
However, because the conditions are highly variable in hospitals, a self-
selected stepwise approach is recommended. Based on the total number
of implemented measures within the 6 blocks (minimum, n = 0;
maximum, n=107) and theweighted degree of implementation (multi-
plier of 0, “none/rarely”, b10%; 1, “moderate”, 10%-50%; or 2, good, N50%),
the total number of points can be calculated (minimum, 0; maximum,
n = 214). The total number of points may then be assigned to a
semiquantitative PBMprogram level. Themoremeasures successfully im-
plemented, the higher the total PBM score, and the higher the semiquan-
titative PBMprogram level (eg, bronze, silver, gold, platinum, or diamond,
respectively; Supplementary Figure S1 in the Supplementary data).
Using these bundles checklists, 2 scenarios might be feasible:
(i) internal self-assessment, for example, to start a project or to advance
ongoing projects similar to quality management initiatives, and/or (ii)
external assessment for peer review of PBM/audit of PBM/accreditation
for PBM.
Block 1: PBM Project Management
Involvement of Key PBM Stakeholders
To recruit a general PBM coordinator is one of the most important
tools to the success of any PBM program (Table 1). The PBM coordinator
has a central role for transparency, communication, networking, educa-
tion, documentation, andbenchmarking. Therefore,we suggest protected
time (eg, 50% dedicated effort) to run the PBM program, as time and
resource constraints are common and reasonable hamper project
management. The PBM coordinator and her/his team should engage in
early communication to key stakeholders, for example, chief medical
ofﬁcer, chief executive ofﬁcer, surgeons, anesthesiologists, intensive
care specialists, nurses, transfusion medicine specialists/transfusion
committee, gastroenterologists, hematologists, cardiologist, general prac-
titioners, and ﬁnance administrative and quality management personnel
for a successful implementation and sustainable support. An ofﬁcial
directive from the hospital board of directors may enhance the PBMundles to Facilitate Implementation, Transfus Med Rev (2016), http://
Table 1
Patient Blood Management project management
Block 1: General PBM project management
Involvement of key PBM stakeholders [role]
PBM coordinator with protected time [central role for
communication, networking, education, documentation, and
benchmarking]
0☐ 1☐ 2☐
Hospital board of directors (eg, chief medical ofﬁcer, chief
executive ofﬁcer, chief nursing ofﬁcer) [support; ofﬁcial directive]
0☐ 1☐ 2☐
Surgeons (eg, orthopedic/trauma, cardiac, vascular, visceral,
trauma, urology, neurosurgery) [interdisciplinary consensus]
0☐ 1☐ 2☐
Anesthesiologists/intensive care specialists [central role for
perioperative care]
0☐ 1☐ 2☐
Transfusion medicine specialists/transfusion committee
[prevention of blood wastage, optimal blood use, changes in
donor blood management]
0☐ 1☐ 2☐
Internists/gastroenterologists/hematologists/cardiologists/
nephrologists [anemia management, optimal blood use]
0☐ 1☐ 2☐
General practitioners/family doctors [determine the necessity for
elective surgery, assign patients to a hospital, preoperative anemia
management]
0☐ 1☐ 2☐
Patient's representative [need to be informed about the different
alternatives to treat anemia/create awareness]
0☐ 1☐ 2☐
Pediatrics [mainly refers to blood conservation strategies] 0☐ 1☐ 2☐
Central laboratory/laboratory scientists [smaller blood
collecting tubes]
0☐ 1☐ 2☐
Pharmacists/purchasing department [introduction of new
drugs for the management of anemia and coagulopathy]
0☐ 1☐ 2☐
Information technology department [sampling of routine data
and key performance metrics]
0☐ 1☐ 2☐
Finance department [ﬁnance experience for program budget
plan, initial project costs; hospital-wide cost savings]
0☐ 1☐ 2☐
Quality management [project management experience; PBM
as a ﬁxed part of a quality improvement initiative]
0☐ 1☐ 2☐
Public affairs [dissemination channels/marketing of the PBM
project (eg, via journals/Intranet/e-mails/posters/roll-ups/press
conferences)]
0☐ 1☐ 2☐
Undergraduate and postgraduate education
Undergraduate education (nursing school/medical school) 0☐ 1☐ 2☐
Postgraduate education of physicians/clinicians (lectures,
workshops; initial and once a year)
0☐ 1☐ 2☐
Postgraduate education of nurses (intensive care unit, normal
ward; initial and once a year)
0☐ 1☐ 2☐
Certiﬁcate (eg, by online E-learning courses)—to enhance PBM
education and knowledge transfer
0☐ 1☐ 2☐
Local standard operating procedures/protocols
Standard operating procedures for PBM
Anemia management 0☐ 1☐ 2☐
Coagulation management 0☐ 1☐ 2☐
Blood conservation 0☐ 1☐ 2☐
Optimal blood use/transfusion of blood products (list of index
procedures for “type and screen” or “type and crossmatch (and
supply)”)
0☐ 1☐ 2☐
Massive hemorrhage protocols (including such as damage
controlled surgery, arterial embolization, hemotherapy algorithm)
Massive hemorrhage (in general) 0☐ 1☐ 2☐
Postpartum hemorrhage 0☐ 1☐ 2☐
Trauma associated hemorrhage 0☐ 1☐ 2☐
Cardiac surgery associated hemorrhage 0☐ 1☐ 2☐
4 P. Meybohm et al. / Transfusion Medicine Reviews xxx (2016) xxx–xxxprogram by adding authority. In addition, the following stakeholders
should also be involved at an early stage: central laboratory for smaller
blood collecting tubes [51,52], Information Technology Department for
sampling of certain routine data andkey PBMperformancemetrics, phar-
macists for the introduction of new drugs for the management
of anemia and coagulopathy, and patients' representatives. Patients
and their relatives should have access to information regarding PBM,
including the risks and beneﬁts of blood transfusion, alternatives and
adjuvant options, and an explanation of restrictive practice. In collabora-
tion with the department for public affairs, an active marketing and
dissemination strategy is recommended for the promotion of the
desired paradigm shift in transfusion practice and to make sustainable
progress in implementation of PBM. For example, a distinctive PBM
logo might be placed on hospital Web page, posters, pens, shirts, ﬂyers,
nametags, and ties to establish a “brand.” Other ways to propagate thePlease cite this article as: Meybohm P, et al, Patient Blood Management B
dx.doi.org/10.1016/j.tmrv.2016.05.012PBM concept are press conferences and meetings with journalists from
medical and general newspapers as well as television delegates. Further
general dissemination channels are suggested, for example, journals,
Intranet, emails, posters, roll-ups, social media, and others.
Undergraduate and Postgraduate Education
A comprehensive PBM education program should be developed for
emergency and elective admissions. This should be targeted to medical
students, physicians, nurses, pharmacists, and other health care staff
and focused on PBM program's goals, structure, and scope. Patient
blood management education is also recommended for both inpatients
and outpatients, surgical patients, and interventional and endoscopic
units. Educational activities should occur initially and regularly, at least
annually, and should be endorsed by public and medical authorities.
The learning materials should be easily accessible, for example, via a
Web site [53], Intranet, or a central virtual room for documents, guide-
lines, posters, education materials. As hemotherapy and transfusion
medicine have been taught inadequately at many medical schools in
the past [54,55], it would be beneﬁcial for the relevant medical staff to
pass online e-learning courses to receive a “PBM certiﬁcate” [56–58].
In most EU countries, physicians have to attend further education con-
stantly to obtain credit points and to preserve professional competence.
In this respect, PBM lectures andworkshops need to be created toprovide
an ideal platform for training.
Local Standard Operating Procedures/Protocols
Standard operating procedures (SOPs) are crucial for many aspects of
a PBM program. Therefore, written interdepartmental SOPs, for example,
clinical protocols, guidelines, visual aids, and checklists, focusing on the 4
strategies of PBM need to be available to the staff at any time. These SOPs
will facilitate implementation, practice, and process and will ensure
sustainability of the PBM program. Risk-adjusted protocols and lists of
index procedures should be developed for “type and screen” in patients
with lower risk of bleeding/transfusion and “type and crossmatch” or
rather “type and crossmatch and temporary supply” in patients with
higher risk of bleeding/RBC transfusion (eg, N10% probability threshold
of RBC transfusion), respectively. Alternatively, to decrease the amount
of time spending to assign or crossmatch status, the maximum surgical
blood order schedule described by Friedman et al [59] could be imple-
mented. A massive hemorrhage protocol should be available that en-
courages early detection, deﬁnitive intervention, and treatment of acute
hemorrhage according to an established algorithm [40,42,60–62].
Where clinically appropriate, this protocol includes damage-controlled
surgery, early return to the operating room for correction of a surgical
source of bleeding, early referral for interventional radiology, “balanced
ratio” of RBCs to plasma to platelets and embolization, and early use
of endoscopy/colonoscopy. Where indicated, massive hemorrhage pro-
tocols should be extended by speciﬁc algorithms for different subgroups
of high-risk patients, for example, postpartum, trauma, cardiac surgery,
or transplantation of solid organs with associated hemorrhage. Hemor-
rhage protocols should include guidelines for laboratory testing
(including viscoelastic testing) and hemotherapy (including transfu-
sion of RBC, plasma, platelets, cryoprecipitate, and factor concentrates).
Block 2: First Strategy—Manage Patient's Anemia
Preoperative Management of Anemia (Subgroup of Surgical Patients)
A full blood count is a widely available low-cost laboratory test and
should be performed on all patients at presentation or betterwith referral
from primary care for operation (Table 2). If this cannot be done, a list of
elective surgical procedures forwhich preoperative anemiamanagement
screening is most likely reasonable should be designed. For example,
these may include the surgical procedures with a greater than 10%
probability of RBC transfusion. Patients scheduled for one of these proce-
dures should be identiﬁed and assessed ideally 3 to 4 weeks before
surgery to allow sufﬁcient time to diagnose and manage anemia, unless,undles to Facilitate Implementation, Transfus Med Rev (2016), http://
Table 2
Anemia management
Block 2: First strategy—manage the patient's anemia
Preoperative management of anemia (subgroup of surgical patients)
Diagnosis of anemia
Identiﬁcation of anemic patients (screening) 0☐ 1☐ 2☐
Diagnosis of iron deﬁciency anemia (eg, blood count, ferritin,
transferrin saturation, calculation of the individual iron deﬁcit)
0☐ 1☐ 2☐
Diagnosis of vitamin B12 or folic acid deﬁciency 0☐ 1☐ 2☐
Extended diagnostic of anemia (eg, consultant for
gastroenterology, endoscopy; hematology, bone marrow biopsy)
0☐ 1☐ 2☐
Diagnosis of anemia ideally 3-4 wk before surgery 0☐ 1☐ 2☐
Diagnosis of anemia although time to surgery is shorter than 3-4wk 0☐ 1☐ 2☐
Anemia clinic; anemia/PBM nurse 0☐ 1☐ 2☐
Treatment of anemia
Administration of intravenous iron 0☐ 1☐ 2☐
Administration of vitamin B12 and/or folic acid 0☐ 1☐ 2☐
Administration of erythropoietin 0☐ 1☐ 2☐
Optimizing cardiovascular and pulmonary function to improve
tolerance of anemia
Increase of oxygen delivery (increase of inspiratory oxygen
concentration); decrease of oxygen consumption
0☐ 1☐ 2☐
Hemodynamic monitoring in high-risk procedures/patients
(normovolemia, optimization of cardiac output)
0☐ 1☐ 2☐
Acute normovolemic hemodilution 0☐ 1☐ 2☐
Management of anemia in hospitalized patients and/or after surgery
Diagnosis of anemia
Diagnosis of iron deﬁciency anemia 0☐ 1☐ 2☐
Treatment of anemia
Administration of intravenous iron 0☐ 1☐ 2☐
Administration of erythropoietin 0☐ 1☐ 2☐
Absence of unnecessary therapies, eg, “top up” RBC transfusion 0☐ 1☐ 2☐
Table 3
Optimization of coagulopathy
Block 3: Second strategy—optimizing coagulopathy
Preoperative management of coagulopathy
Algorithm for management of patients with oral/parenteral
anticoagulation and/or antiplatelet therapy
0☐ 1☐ 2☐
Questionnaire/tests of hemostasis 0☐ 1☐ 2☐
Hemostasis management in hospitalized patients
Physiological conditions of hemostasis
Body temperature N36°C (normothermia) 0☐ 1☐ 2☐
pH N 7.2/ionized Ca2+ N 1.1 mmol/L 0☐ 1☐ 2☐
Point-of-care diagnostic in coagulopathy
Coagulation system (eg, viscoelastic methods) 0☐ 1☐ 2☐
Platelet function (eg, aggregometric methods) 0☐ 1☐ 2☐
Use of a coagulation algorithm for administration of blood
products, clotting factor concentrates, tranexamic acid
0☐ 1☐ 2☐
Empiric administration of tranexamic acid in certain procedures
(particular in cardiac, orthopedic, transplant surgery, massive
hemorrhage)
0☐ 1☐ 2☐
Empiric therapy of platelet dysfunction (eg, desmopressin) 0☐ 1☐ 2☐
5P. Meybohm et al. / Transfusion Medicine Reviews xxx (2016) xxx–xxxof course, the surgery is of an urgent nature [22,45,63–66]. If the time
interval is shorter than 3 to 4 weeks, any preoperative attempt to diag-
nose and treat anemia is still indicated [48,67,68]. Screening and subse-
quent laboratory testing should be performed to detect anemia and to
allow diagnosis of the common causes of anemia including iron deﬁcien-
cy anemia, anemia of inﬂammation, or folate or vitamin B12 deﬁciency. In
cases of anemia of unclear etiology, extended diagnostic testing and re-
ferral to a specialist should ideally be feasible [63]. It is preferable for
screening to be performed at the time of surgical indication. A
screening-directed laboratory assessment will reduce workload and
costs and, therefore, should be well received by hospital/department
managers [22]. In addition, this will mitigate the diagnostic-associated
blood loss postsurgery. Noninvasive screening monitoring of hemoglobin
may further reduce workload, blood loss, and costs for anemia screening,
although further technical developments areneeded tooptimizeprecision
[69]. An anemia clinic and/or a PBM nurse practitioner with delegated
authority to carry out speciﬁed clinical procedures are additional ways
to comply with the PBM concept. Outpatient preoperative treatment
with parenteral iron, vitamin B12, folic acid, and/or erythropoiesis-
stimulating agents should be used when clinically indicated.
Optimizing Cardiovascular and Pulmonary Function to Improve Tolerance
of Anemia
A patient's physiologic tolerance of anemia can be harnessed by
optimizing oxygenation, decrease of oxygen consumption, ensuring
normovolemia, and optimized hemodynamics (eg, invasive hemody-
namic monitoring in high-risk procedures) [70]. Consider intraopera-
tive acute normovolemic hemodilution to reduce allogeneic blood
transfusion in patients at high risk for excessive bleeding (eg, major
cardiac, orthopedic, thoracic, or liver surgery) [38].
Management of Anemia in Hospitalized Patients and/or After Surgery
Comparable to preoperative anemia management, there should also
be an algorithm for diagnosis and therapy of anemia in hospitalized
patients and/or after surgery, including workup of iron deﬁciency,Please cite this article as: Meybohm P, et al, Patient Blood Management B
dx.doi.org/10.1016/j.tmrv.2016.05.012calculation of iron deﬁcit, and the use of intravenous iron, vitamin B12,
folic acid, and/or erythropoiesis-stimulating agents, when indicated
[47,48,71,72]. Unnecessary therapies such as “top up” transfusion should
be prevented.
Block 3: Second Strategy—Optimizing Coagulopathy
Preoperative Management of Coagulopathy
Local standard operation procedures (eg, questionnaires/tests of
hemostasis, algorithms for bridging in patients with preoperative
anticoagulants, and antiplatelet medications) should clearly deﬁne
preoperative evaluation and management of coagulopathy (either
unknown or drug induced) [73,74] (Table 3).
Hemostasis Management in Hospitalized Patients
Adequate coagulation management needs to be a precondition
before RBC transfusion is considered. In this respect, the use of a coagu-
lation algorithm is recommended [75,76]. In addition, basic conditions
for hemostasis (eg, temperature, calcium, pH), reversal of anticoagu-
lants, point-of-care diagnostics in coagulopathic patients, optimized
coagulation management with the use of clotting factor concentrates,
and the (empiric) use of antiﬁbrinolytic agents or desmopressin are
further important considerations [40,60,77,78]. The one-size-ﬁts-all
dogma of fresh frozen plasma (FFP) transfusion to correct or prevent
coagulopathy needs be critically questioned due to known risks of allo-
geneic blood products [40]. Similarly, evaluation of platelet function
should be considered ﬁrst in the setting of surgical and interventional
procedures to tailor treatment of coagulopathy, instead of liberal trans-
fusion of numerous platelet concentrates [40].
Block 4: Third Strategy—Interdisciplinary Blood Conservation Modalities
Reduction of Diagnostic-Associated Blood Loss
A key element of PBM is prevention of blood being unnecessarily
removed from the patients, particular by reducing phlebotomy blood
loss within daily laboratory analyses (Table 4). This can be achieved in
several ways. First, as mentioned above, early preoperative anemia
screening is instrumental in reducing the need for phlebotomy when
the patient is hospitalized or postsurgery. Second, when sampling
blood, phlebotomists should use the smallest collection tube size that
is practical for the required analysis. In addition, reducing unnecessary
laboratory tests, unnecessary blood culture draws, the frequency of
sampling, the “discard” volume when samples are obtained from
indwelling lines, and the blood waste by the use of closed in-line ﬂush
blood sampling devices for arterial and central venous lines are recom-
mended [51,52,79]. In addition to the medical beneﬁts of this approach,
patients will also appreciate fewer painful blood draws.undles to Facilitate Implementation, Transfus Med Rev (2016), http://
Table 4
Blood conversation strategy
Block 4: Third strategy—interdisciplinary blood conservation modalities
Reduction of diagnostic-associated blood loss
Reduced size of blood collection tubes
EDTA tube 0☐ 1☐ 2☐
Citrate tube 0☐ 1☐ 2☐
Lithium-heparin/serum tube 0☐ 1☐ 2☐
Type and screen tubes 0☐ 1☐ 2☐
Restrictive frequency of blood collection 0☐ 1☐ 2☐
Appropriate timing of postoperative blood tests and not daily
judicious use/“weekend” plan
0☐ 1☐ 2☐
Reduced sampling for blood cultures in daily routine (limit to
established indications)
0☐ 1☐ 2☐
Closed in-line ﬂush devices (arterial pressure transducer
systems, central venous blood collection)
0☐ 1☐ 2☐
Reduction of surgery-related blood loss (subgroup of surgical patients)
Extreme attention to minimize blood loss (eg, diathermy for
tissue dissection), hemostatic adjuncts
0☐ 1☐ 2☐
Laparoscopic surgery/minimal invasive techniques/modern
surgical instruments
0☐ 1☐ 2☐
Limited numbers of swabs for blood absorption/swab washing
and cell salvage (“single swab”)
0☐ 1☐ 2☐
Controlled hypotension (if no contraindication is present) 0☐ 1☐ 2☐
Autologous blood collection and retransfusion (cell salvage)—
intraoperatively and postoperatively
Nononcological procedures: if expected blood loss N500 mL 0☐ 1☐ 2☐
Oncological procedures: if massive blood loss 0☐ 1☐ 2☐
Oncological procedures: if expected blood loss N500 mL
(radiation of washed blood; ﬁltration using leukocyte
depletion ﬁlters)
0☐ 1☐ 2☐
Cardiac surgery
Small extracorporeal circuits (priming volume b1.2 L; 3/8″
lines; minimized extracorporeal circuits)
0☐ 1☐ 2☐
Extracorporeal circuits (retrograde autologous priming; blood
cardioplegia, modiﬁed ultraﬁltration/hemoﬁltration)
0☐ 1☐ 2☐
Bloodless saphenous vein graft removal/immediate wound
closure/endoscopic vein removal
0☐ 1☐ 2☐
Table 5
Optimal blood use
Block 5: Fourth strategy—optimal blood use with patient-centered decision making
Patient-centered decision making
Individual PBM plan with transfusion triggers based on the
patient's risk proﬁle/tolerable erythrocyte deﬁcit
0☐ 1☐ 2☐
Written patient information form/informed consent for
allogeneic blood products (in emergency after transfusion)
0☐ 1☐ 2☐
Clinician who ordered blood products can be identiﬁed
(important for feedback and audit)
0☐ 1☐ 2☐
Single-unit policy (RBC units, platelet concentrate) 0☐ 1☐ 2☐
Intelligent electronic ordering system for blood products
(including patient's lab results, alert function)
0☐ 1☐ 2☐
Use of dosage for blood components instead of units 0☐ 1☐ 2☐
Indication list for each of the following hemotherapy products
(eg, pocket card, supply note, poster, etc)
RBC units 0☐ 1☐ 2☐
Platelet concentrate 0☐ 1☐ 2☐
FFP units 0☐ 1☐ 2☐
Coagulation factors (prothrombin complex concentrate,
ﬁbrinogen, recombinant VIIa, recombinant XIII)
0☐ 1☐ 2☐
Documentation of the indication for each of the following
hemotherapy products (eg, by paper-/electronic-based ordering)
RBC units 0☐ 1☐ 2☐
Platelet concentrate 0☐ 1☐ 2☐
FFP units 0☐ 1☐ 2☐
Coagulation factors (prothrombin complex concentrate,
ﬁbrinogen, recombinant VIIa, recombinant XIII)
0☐ 1☐ 2☐
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The surgical use of blood and blood products has decreased signiﬁ-
cantly in the last 5 years. This can be attributed primarily to surgical
technique, role of laparoscopic surgery, and physicians' mindfulness re-
garding limiting blood loss. Nevertheless, judicious use of diathermy
dissection, appropriate suction and cell salvage, and controlled hypo-
tension in bleeding patients aswell as application of topical haemostatic
agents/tissue adhesives are also important tools to reduce surgery-
related blood loss.
The use of intraoperative/postoperative autologous blood collection
and retransfusion should be standardized including indications and con-
traindications [80]. In oncology patients, cell saving might be indicated
after radiation or ﬁltration of washed blood, using leukocyte depletion
ﬁlters or in cases of massive bleeding [81]. In addition, a focus on the
number of swabs used for blood absorption and the reuse of washed
swabs combined with autologous cell salvage allows reduction of
irreversible blood loss. In cardiac surgery, a wide spectrum of blood-
sparing techniques have been described in the literature, for example,
minimized extracorporeal circuits, retrograde autologous priming, modi-
ﬁed ultraﬁltration, blood cardioplegia, and meticulous hemostasis in
saphenous vein graft removal [82].
Block 5: Fourth Strategy—Optimal Blood Use With Patient-Centered
Decision Making
Patient-Centered Decision Making
A predeﬁned individual PBM plan with transfusion triggers based on
the individual patient's risk proﬁle and calculation of tolerable erythro-
cyte deﬁcit is suggested (Table 5). To optimize utilization of blood
products and to identify the ordering physician in case of any audit, it is
beneﬁcial to adopt a physician order entrywith a clinical decision support
based on electronicmedical records [14,17]. For the purposes of obtainingPlease cite this article as: Meybohm P, et al, Patient Blood Management B
dx.doi.org/10.1016/j.tmrv.2016.05.012informed consent from a patient for the transfusion of allogeneic blood
products before transfusion (or after it, when urgently needed), hand-
written or computer-generated forms (ideally a separate sheet of
paper) should be used that comprehensively includes a detailed outline
of transfusion beneﬁts, risks, and alternatives. Both using a system that
electronically identiﬁes patients to improve the safety and efﬁciency
of the blood transfusion process and appropriate verbal and written
information to the patient and/or carer were also highlighted by the
recent recommendations from the National Institute for Health and
Care Excellence on blood transfusion [83].
Policies andprocedures for ordering, dispensing, and transfusingblood
components need to comply with available national guidelines [83–85].
Indication for transfusion takes into consideration patient speciﬁc factors
(eg, age, diagnosis, comorbidity), laboratory values (eg, hemoglobin,
platelet count, coagulation testing), presence or absence of bleeding, and
physiologic factors (eg, oxygenation, hemodynamic status). When RBC
transfusion is clinically indicated in the nonbleeding patient, only a single
unit of RBC should be prescribed, followed by clinical reassessment of the
patient (“single unit policy”; “transfuse and assess strategy”) [17,19].
Interestingly, the general terminology for blood components is unit,
bags, and others, but the concept of dosage is still not used apart from
coagulation factors. There might be signiﬁcant variations in volume and
content of blood component units, as a reﬂection of donors' characteristics.
Pocket cards, supply notes, posters, apps, and others can spread edu-
cation regarding the indication of hemotherapy products. In addition,
documentation of the indication of the total spectrum of hemotherapy
products can be facilitated by either paper- or computer-based ordering
system with required checkboxes. When the ordering physician must
indicate the reason for application as part of the ordering process, this
allows concurrent utilization self-review [14]; importantly, this effective
promotion of hemotherapy practices has been shown to be associated
with improved clinical patient outcomes [15].
Block 6: PBM-Related Metrics, Patient's Outcome, Benchmark
Patient Blood Management–Related Metrics
Patient blood management–related metrics and blood usage should
be collated itemized for each department to allow identiﬁcation of po-
tential areas for improvement due to overutilization or underutilization
and, if desired, even more speciﬁcally down to physician groups and/orundles to Facilitate Implementation, Transfus Med Rev (2016), http://
Table 6
Patient Blood Management–related metrics
Block 6: PBM-related metrics/patient's outcome/benchmark
PBM-related metrics
Anemia—itemized for each department with percentage of patients
Preoperative anemia 0☐ 1☐ 2☐
Hospital-acquired anemia 0☐ 1☐ 2☐
Treated anemic patients (eg, parenteral iron, vitamin B12,
folic acid, erythropoiesis-stimulating agents)
0☐ 1☐ 2☐
Use of blood conservation techniques—itemized for each department
with number of units and percentage of patients
Use of hemostatic agents (tranexamic acid, desmopressin) 0☐ 1☐ 2☐
Use of cell salvage 0☐ 1☐ 2☐
Hemotherapy product use—itemized for each department with
number of units/dosage and percentage of patients
Blood products (RBC units, platelets concentrates, FFP units) 0☐ 1☐ 2☐
Coagulation factors (prothrombin complex concentrate,
ﬁbrinogen, recombinant VIIa, XIII)
0☐ 1☐ 2☐
Transfusion episodes where a single unit of RBCs/platelet issued 0☐ 1☐ 2☐
Indications for blood product use—mean pretransfusion levels
(hemoglobin, platelet count, INR)
0☐ 1☐ 2☐
Blood product use that falls outside of hospital or professional
transfusion guidelines
0☐ 1☐ 2☐
Blood wastage—number of units
Crossmatch (supply)/transfusion ratio (aim: as low as possible;
ratio b1.7:1)
0☐ 1☐ 2☐
Discarded blood products (RBC units, platelet concentrates,
FFP units)
0☐ 1☐ 2☐
Report to clinicians/administrative departments about PBM-related
metrics (once a year)
0☐ 1☐ 2☐
Patient's outcome
Mortality (inhospital) 0☐ 1☐ 2☐
Morbidity (eg, ICD-10 codes)
Infections (sepsis, pneumonia), acute renal failure, acute
myocardial infarction, acute ischemic stroke
0☐ 1☐ 2☐
Length of stay in hospital/intensive care unit 0☐ 1☐ 2☐
Hemovigilance (transfusion reactions, transfusion-associated
cardiac overload, transfusion-associated acute lung injury)
0☐ 1☐ 2☐
Benchmarking
Internal/external benchmarking (eg, for selected surgical procedures) 0☐ 1☐ 2☐
Membership of a PBM network 0☐ 1☐ 2☐
Program budget for PBM
Initial/ongoing project costs (personnel resources, dissemination);
PBM-related cost savings (reduced blood products, laboratory
analyses)
0☐ 1☐ 2☐
Hospital audit for PBM
Participation in hospital audit for PBM practice and transfusion
decisions in a sample of scheduled cases
0☐ 1☐ 2☐
Hospital accreditation for PBM
Participation in a hospital certiﬁcation (accreditation) program
for PBM
0☐ 1☐ 2☐
Abbreviations: INR, international normalized ratio; ICD-10, International Statistical Classiﬁ-
cation of Diseases, 10th Revision.
7P. Meybohm et al. / Transfusion Medicine Reviews xxx (2016) xxx–xxxindividual clinicians (Table 6). Patient blood management–related
metrics include percentage of patients with diagnosis and therapy of
anemia and use of blood conservation techniques as well as use of
hemotherapy products. Data should also include transfusion episodes
where a single unit of RBC/platelet issued, indications for blood
product use with mean pretransfusion levels, and blood product use
that falls outside of hospital or professional transfusion guidelines, for
example, patients receiving RBC transfusion with a pretransfusion Hb
of greater than 8 g/dL (5 mmol/L), nonbleeding hematooncology pa-
tients receiving a platelet transfusion with a pretransfusion platelet
count of greater than 10 000/μL. By this way, amonitoring and feedback
systemmay be useful, which electronically registers each hemotherapy
product as well as corresponding laboratory data and reports results to
clinicians regularly, as it has recently been implemented at the University
Hospital of Zurich [86].
Analysis of the institution's own data about the ratios of both “cross-
match to transfused” and “supplied to transfused” blood units, measures
to decrease this ratio reﬂecting overordering of blood compared with
actual transfusion, immediate canceling of requested and returning
of temporary supplied but unneeded units, and analysis of discardedPlease cite this article as: Meybohm P, et al, Patient Blood Management B
dx.doi.org/10.1016/j.tmrv.2016.05.012blood products allow optimized utilization of the blood products and
reduction of unnecessary bloodwastage. All PBM-relatedmetrics should
be reported to involved clinicians and administrative departments, for
examples, once a year.
Patient's Outcome
For an effective change process, one needs to ﬁrst establish what the
current PBM practice is. Then one can share the data with physicians,
plan and implement any interventions, and continue to audit and
track utilization to evaluate the change andmonitor success. The impact
of PBM on clinical outcomes should be evaluated on a regular basis
(eg, once a year). Clinical end points could be monitored by means of
the hospital information system, where the relevant diagnoses are
encoded. In addition, data should include inhospitalmortality and length
of stay at both the intensive care unit and the hospital. In accordance
with current regulations, all patient-related data need to be anonymized
to allow analysis. Hemovigilance data, including transfusion reactions,
transfusion-associated cardiac overload, and transfusion-associated
acute lung injury, need to be reported.
Benchmarking
As PBM has been identiﬁed as a strategy to improve patient out-
comes, internal and/or external benchmarking may be one of the
most important tools in medical change management and to ensure
sustainability [87].
In addition, collaboration within a PBM network project at different
levels (eg, local/regional/national/European-wide) would be worth-
while. For example, membership could imply free access to master
ﬁles, documents, checklists, central data collection, data analysis,
benchmarking of PBM-related metrics, and key clinical outcomes for
speciﬁed procedures.
Program Budget for PBM
Adetailed programbudget needs to cover initial and ongoing project
costs for personnel resources, equipment needs, and other project-
related resources that support dissemination. A PBMprogram, however,
can result in hospital-wide cost savings, particular due to reduced costs
of blood products, blood wastage, laboratory analyses, and reduced
expenses associated with adverse events, thereby, successful implemen-
tation of PBMmay fund the program itself [49].
Hospital Audit for PBM
Hospital audit highlights areas of good practice as well as variability
in practice and enables hospitals to prioritize implementation of PBM
initiatives. In the UK, for example, the auditor collects information on
PBM practice and transfusion decisions in a sample of scheduled surgi-
cal cases who have received RBC transfusion on a case-based tool [88].
Hospital Accreditation for PBM
In future, the quality of PBM programs within the local hospital may
be assessed by hospital accreditation. Accreditation may be granted
for different PBM-related topics, for example, anemia management,
management of coagulopathy, blood conservation, or optimal blood
use. In Australia,where the Australian Commission on Safety andQuality
in Health Care has made PBM a national priority, implementation of
PBM is 1 of the 10 National safety and quality health service standards
[89]. Furthermore, the A` and the Joint Commission recently announced
a collaborative partnership to provide a joint hospital certiﬁcation
(accreditation) program for PBM to promote patient safety and quality
by combining an internationally accepted quality management system
structure with appropriate PBM technical requirements [7]. This
promoted an increased focus on PBM by hospital executives and pro-
vided an opportunity to promote PBM as a key mechanism to improve
patient outcomes.undles to Facilitate Implementation, Transfus Med Rev (2016), http://
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Despite the demonstrated beneﬁts of PBM,many barriers limit trans-
lation of PBM guidelines into clinical practice worldwide, particularly
due to lack of knowledge, lack of interdisciplinary commitment, lack of
resources, and general concerns. Under the precondition of applied
change management principles, an effective PBM program needs to
include a comprehensive spectrum of administrative and clinical stan-
dards of PBM principles. Strategies for overcoming the hurdles often
include the use ofmultimodal “care bundles” and speciﬁc designedmea-
sures according to local conditions. Therefore, the PBM “bundles”
approach, which incorporates individual, low-threshold stepwise selec-
tion of the most feasible measures, depending on local cultural condi-
tions, may serve as a new concept of “how to implement PBM.” It
should enable PBM's patient-centered approach to be delivered in a
way that is also hospital centered and, therefore, compatible with each
institution. The institution's initial success should drive further motiva-
tion and activities in the ﬁeld of PBM.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tmrv.2016.05.012.
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